Mobia Medical MOBI 深 沪
已收盘 11-13 16:00:00 美东时间
13.17
-0.140
-1.05%
华盛通- 最 高13.4689
- 今 开13.39
- 成交量 16.06万股
- 最 低 12.6561
- 昨 收 13.31
- 总市值 4.39亿
- 52周最高 15.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.13
- 委 比 -81.17%
- 总股本 3332.79万
- 历史最高 15.29
- 量 比 0.74
- 振 幅 6.11%
- 历史最低 2.13
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mobia Medical Raises FY2026 Sales Guidance from $54.000M-$56.000M to $57.000M-$57.500M vs $55.030M Est
Mobia Medical (NASDAQ:MOBI) raises FY2026 sales outlook from $54.000 million-$56.000 million to $57.000 million-$57.500 million vs $55.030 million estimate.
11-06 05:29
Mobia Medical Reports Third Quarter 2026 Financial Results
Mobia Medical reported a 73% revenue increase in Q3 2026, raising its full-year 2026 revenue guidance to $57.0 million to $57.5 million. The company achieved an 83.2% gross margin and expanded its active territories. It also secured inclusion of paired VNS in the updated AHA stroke recovery guidelines, highlighting its evidence-based approach. Operating expenses rose 71%, and the net loss per share improved due to increased shares outstanding. Ca...
11-05 21:05
Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference
Mobia Medical, Inc. announced that its management will participate in a fireside chat and host investor meetings at the 8th Annual Wolfe Research Healthcare Conference on November 10, 2026. The fireside chat will be live and archived on the company’s website. Mobia Medical specializes in stroke recovery solutions, offering the Vivistim® Paired VNS™ System, an FDA-approved implantable device to improve upper limb function in chronic ischemic strok...
11-03 21:05
美股大行评级 | 潜在涨幅203.03%！BTIG上调Rapport Therapeutics目标价至89美元，维持"买入"评级
今日重点评级关注：BTIG：维持Rapport Therapeutics"买入"评级，目标价从75美元升至89美元；摩根士丹利：维持希捷科技"超配"评级，目标价从1187美元升至1200美元
10-21 12:30
BTIG Reiterates Buy on Mobia Medical, Maintains $19 Price Target
BTIG analyst Ryan Zimmerman reiterates Mobia Medical (NASDAQ:MOBI) with a Buy and maintains $19 price target.
10-21 00:37
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 0.1% on Friday. Shares of Gap Inc (NYSE:GAP) rose sharply as the company reported better-than-expected second-quarter earnings and raised their FY26 EPS guidance above estimates. Revenue came in at $3.65 billion, versus estimates of $3...
08-28 22:22
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
Mobia Medical's Vivistim® Paired VNS™ System has been recognized in the 2026 American Heart Association and American Stroke Association guideline as a treatment option to improve upper-limb function in chronic stroke survivors. The guideline highlights the use of vagus nerve stimulation paired with high-dose task-specific training. Mobia Medical's system is the only FDA-approved solution for this approach. The recognition validates the technology...
08-28 11:30
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Reiterates Buy on Mobia Medical, Maintains $19 Price Target
BTIG analyst Ryan Zimmerman reiterates Mobia Medical (NASDAQ:MOBI) with a Buy and maintains $19 price target.
08-12 17:56
Mobia Medical Sees FY2026 Sales $54.000M-$56.000M vs $53.504M Est
Mobia Medical (NASDAQ:MOBI) sees FY2026 sales of $54.000 million-$56.000 million vs $53.504 million analyst estimate.
08-12 04:31
